Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial - Test2 - elhamkhani - TriplyDB

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

http://www.wikidata.org/entity/Q28304807

about

Lupus Nephritis in Asia: Clinical Features and Management Current and emerging treatment options in the management of lupus Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications Belimumab in systemic lupus erythematosus Use of biologics in SLE: a review of the evidence from a clinical perspective B-cell survival factors in autoimmune rheumatic disorders Belimumab in systemic lupus erythematosus: a perspective review Cellular targeting in autoimmunity The rationale for BAFF inhibition in systemic lupus erythematosus Profile of atacicept and its potential in the treatment of systemic lupus erythematosus Effect of TACI signaling on humoral immunity and autoimmune diseases B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production Unmet medical needs in systemic lupus erythematosus Drugs derived from phage display: from candidate identification to clinical practice Approaches for estimating minimal clinically important differences in systemic lupus erythematosus Neuropsychiatric lupus: a mosaic of clinical presentations Targeting dendritic cell function during systemic autoimmunity to restore tolerance Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities From BILAG to BILAG-based combined lupus assessment-30 years on Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus What is new in the management of rapidly progressive glomerulonephritis?Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis The pathogenesis of systemic lupus erythematosus—an update CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Patient-reported outcomes in lupus clinical trials with biologics.First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.The pathogenesis, diagnosis and treatment of lupus nephritis.Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels.Failure of a systemic lupus erythematosus response index developed from clinical trial data: lessons examined and learned.Novel treatments for immune thrombocytopenia.Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease.

P2860

Q26740487-AE650FAB-840C-43BC-A90F-1466D60BFE59 Q26741266-5A4833EE-C033-4AA3-AFA9-EE6EAD01AA51 Q26774880-630FCC16-2C7D-4614-80DE-96739C19A3BA Q26775756-11AFB375-2D05-4E11-98C2-C5DBBE47ADCC Q26778277-69512469-2B63-4992-B787-84E90ECFE9C7 Q26783652-5F361E7A-D639-4888-96CB-96AC5B125020 Q26796484-FDBF148F-559E-4703-9914-6CD6E076945A Q26796486-1BB89204-9C82-458D-8F7A-E742CA8D354B Q26824580-EB0A7AFB-CAFF-4A84-81FC-5D0994614D50 Q26827373-092CD9BF-8A30-41D7-9BE0-8E4183235A42 Q26849719-32512611-B91B-4B12-9208-00EB1C7CE314 Q26995571-523249D0-4DC9-4AF9-BD4A-32236505D99A Q26996644-0B7321F2-6EA1-4EA0-9A23-3A978AA3FCAA Q27005906-9BE5D534-52C0-405C-865F-ACF9F35C03A4 Q27007101-C008B3A6-3FFC-4F10-80E3-913BBE81DA86 Q27021623-9A69417B-F4F7-4416-AB14-4B15CEA8FA0F Q27027588-323B5B90-EF13-4618-ACD7-606337390507 Q27687098-4A0F2C33-5648-4201-93D5-33B432D8F06E Q28067781-E118B6F0-B6A3-48DD-AFA1-7F91CBC47432 Q28080571-FC4430F2-AC5A-4445-B6A4-CD9E1CD97836 Q28081809-CFA06CD5-553D-4A2A-B7C8-58F3D5D397FF Q28088753-13C555F2-F18D-4A4F-B746-AF4B4A569655 Q28254310-01B92B06-9947-435B-AD63-AB63DD758118 Q28259540-1FD86E0A-2EE1-4B49-AA34-8C443115852F Q28265144-3C43CBC9-68DC-4113-A721-5E891D122B0F Q28294329-EAA9CA6D-9AF6-4150-9EFB-2A312C528AD7 Q28660706-3C0C872D-EC68-468C-A0E0-E1E36392C91D Q28676968-131F49D3-B138-4F3A-B5DB-F3FEFB3C5228 Q29394347-17FBF4C0-9D85-4996-9BF1-5358F8B879C0 Q30388433-C576C135-C81B-4272-AC19-77F10541D917 Q30391564-D1AE8B07-61F2-48CE-BDD7-48654567331F Q30490276-CD3FB5A9-1E60-4DE0-B6F0-AF6B90205ED6 Q30580226-D1DDE497-606B-4D9A-88B9-5FBEC73E9C84 Q30596968-FED31A09-E300-46F8-8F21-DE235D268DD0 Q30645037-DAFAFF89-56CE-4CD3-BAEB-21254D112097 Q30832522-8CF06275-CA6A-4A81-A44F-F5D497218B7C Q31087724-6ECA684B-3235-4F43-BAD1-F98E4466790A Q31160251-E11EB76A-7854-4AA1-8655-CA17BAD512E4 Q33414132-60889E42-2469-409D-AFE5-B7CB3236D81C Q33431030-B66DEB07-9654-468B-8A02-A54CB3E7A256

P2860

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

http://www.wikidata.org/entity/Q28304807

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@ast

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@en

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@nl

type

label

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@ast

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@en

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@nl

prefLabel

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@ast

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@en

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@nl

P1433

Q28304807-F06AF072-94EF-4880-AB17-943D4402DFA3

P1476

Q28304807-7E2CA14D-B6B1-461E-94DF-0156C1D5AEE9

P2093

Q28304807-0B72FFBA-A2ED-4853-B45A-1AD61E92B8A1

Q28304807-177FBF19-3809-4037-A369-8E9CB70B076E

Q28304807-2736A965-B33D-4566-A6BE-D0B46C62CEDB

Q28304807-3C910298-6644-48BD-9152-38CE1CB26753

Q28304807-4A14A6EA-A150-4BC2-9FAE-60822E8A73CC

Q28304807-4A26F33B-6E19-48EF-B2C2-AFFA0DF10D85

Q28304807-4F75A7BA-8C84-4D55-A480-2BB5662EF0B9

Q28304807-5D23B4F0-43B7-407B-A444-E241E24A7883

Q28304807-9B5D50F0-84A2-44CE-946F-8126930194E3

Q28304807-9B920FFD-20FF-4787-91B7-8AB17A4094B7

P304

Q28304807-20329D64-12C1-434F-9DD5-5A0AAD147878

P31

Q28304807-37BD0576-D2FE-4F3F-B0A2-C6A0A4C415E6

P3181

Q28304807-643A9F09-C2A0-4AEE-8C87-6C5E4490C437

P356

Q28304807-EEFA3988-7087-4D18-9BCB-C3E576CF7A24

P407

Q28304807-05D91869-D189-4982-9CCF-18A0715290DC

P433

Q28304807-232CA963-B558-4549-8221-AB449C004CBA

P478

Q28304807-01B9B4F5-F9A5-48D6-AADB-FE9B69D51095

P50

Q28304807-0E5AC48C-D0BF-4ED3-9CC2-A3F5CEE840E1

Q28304807-94A20CCC-1EF2-4D56-9930-0B97BD940A04

P577

Q28304807-8064F722-B57B-4817-BD45-76D1F703A107

P698

Q28304807-B0FE7325-F41F-4515-A30B-C421DC297038

P921

Q28304807-36B8E75B-8D1B-49F6-8A32-CE4887D0A3D3

Q28304807-642FF3A1-84CF-4F2F-9FA0-96D37AA171FE

Q28304807-AD96C924-A9BC-4F6E-A574-18FD2607967D

P3181

P356

S0140-6736(10)61354-2

P1433

P1476

Efficacy and safety of belimum ...... cebo-controlled, phase 3 trial

@en

P2093

Alberto E Gallacher

http://www.w3.org/2001/XMLSchema#string

Coman Tanasescu

http://www.w3.org/2001/XMLSchema#string

Edmund K-M Li

http://www.w3.org/2001/XMLSchema#string

Eugeny Nasonov

http://www.w3.org/2001/XMLSchema#string

Ho-Youn Kim

http://www.w3.org/2001/XMLSchema#string

Joung-Liang Lan

http://www.w3.org/2001/XMLSchema#string

Lilia Pineda

http://www.w3.org/2001/XMLSchema#string

Manuel G León

http://www.w3.org/2001/XMLSchema#string

Mathew Thomas

http://www.w3.org/2001/XMLSchema#string

Renato E Jimenez

http://www.w3.org/2001/XMLSchema#string

P304

721-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1836975

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(10)61354-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

9767

http://www.w3.org/2001/XMLSchema#string

P478

377

http://www.w3.org/2001/XMLSchema#string

P50

Michelle A. Petri

P577

2011-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21296403

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial